2. Search Result
Search Result
Results for "

fibroblast activation protein α

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Peptides

2

Inhibitory Antibodies

1

Isotope-Labeled Compounds

4

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99902
    Simlukafusp alfa

    FAP-IL2v; RO6874281; RG7461

    		 Interleukin Related Cancer
    Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .
    Simlukafusp alfa
  • HY-161074
    PNT6555

    		FAP Cancer
    PNT6555 is a fibroblast activation protein-α (FAP) inhibitor. PNT6555 has antitumor activity. PNT6555 can be used for imaging of FAP-positive tumors .
    PNT6555
  • HY-176305S
    Neurofilament, U-15N

    		Isotope-Labeled Compounds Neurological Disease
    Neurofilament, U- 15N is the 15N-labeled Neurofilament.
    Neurofilament, U-15N
  • HY-161262
    SB03178

    		FAP Cancer
    SB03178 is a fibroblast activation protein-alpha (FAP) inhibitor. SB03178 can be conjugated with DOTA and can be used for cancer research .
    SB03178
  • HY-P991087
    RO7122290

    		FAP Cancer
    RO7122290 is a bispecific fusion protein carrying a split trimeric 4-1BB (CD137) ligand and a fibroblast activation protein α (FAP) binding site. O7122290 is a FAP-α-targeted 4-1BB agonist that costimulates T cells for improved tumor cell killing in FAP-expressing tumors .
    RO7122290
  • HY-177083
    Faridoxorubicin

    AVA-6000

    		 FAP Cancer
    Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis) .
    Faridoxorubicin
  • HY-136727A
    Ac-LEVD-CHO TFA

    		Caspase Apoptosis Cancer
    Ac-LEVD-CHO (TFA) is an inhibitor of caspase-4. Ac-LEVD-CHO (TFA) can inhibit the expression and secretion of IL-1α expression as well as the activation of caspase-4 induced by the T. denticola periodontal pathogen surface protein Td92 in human gingival fibroblasts. Ac-LEVD-CHO (TFA) can also reduce the apoptosis due to the expression of the dominant negative adenoviral RNA-dependent protein kinase in A549 and PC3 cancer cell lines .
    Ac-LEVD-CHO TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: